Communicating emerging, trusted scientific information to healthcare professionals (HCPs). Pfizer sponsored, intended for U.S. HCPs. Our community guidelines can be found here:

Learn more about Isolated Proctitis and potential treatment with an S1P Receptor Modulator in a webinar by Dr. Marla Dubinsky #ulcerativecolitis .

Now enrolling! . Learn more about a Pfizer clinical trial studying a potential treatment for the prevention of #migraine attacks in children and adolescents with episodic migraine. . #ClinicalTrials #HCPs #neurotwitter

Exciting News! Our latest research on a contemporary mixed phenotype ATTR-CM population, using real-world data from THAOS, is now published. Learn more: #Cardiology #Amyloidosis #THAOS #ATTRCM

Explore the gastroenterologist's role in #IBD preventive care in this new video series. Join IBD experts as they discuss guidelines for primary and secondary prevention and health maintenance needs. #Gastroenterology #inflammation:

Meet Dr. Rashmi Halker Singh from Mayo Clinic, AZ. In our video series, she highlights collaborative care and shares the latest consensus statements from the American Headache Society on acute and preventive migraine interventions. Watch for more!

Migraine Data Update . Read more about the results from a just published open label extension of a preventive treatment study. Full publication: #neurology.#healthcare.#neurotwitter

In our expert series, Dr. Larry Charleston IV discusses the importance of early migraine symptom identification and comorbid conditions. He discusses the ID MigraineTM Screener for busy practitioners. Watch now and stay tuned for more

Currently Enrolling! . Learn more about a Pfizer clinical trial studying a potential treatment for the prevention of #migraine attacks in children and adolescents with episodic migraine. For more information visit . #ClinicalTrials #HCPs #neurotwitter

Explore a recently published subgroup analysis on the safety and patient-reported outcomes of a CGRP receptor antagonist among triptan-naive, triptan-using, and triptan-failure participants. #Migraine #PatientOutcomes

Read a new publication on acute #migraine treatment discussing the efficacy and safety of a CGRP receptor antagonist. This post-hoc analysis used patient-level data to give insights on the potential benefits and risks of treatment. #neurotwitter Learn more

Discover Plain Language Summaries describing key findings of an S1P Receptor Modulator in UC #ulcerativecolitis .

One week left to apply! Pfizer invites organizations to apply to a competitive #grant supporting quality improvement initiatives for shared decision making in #hemophilia patient care. Learn more at Deadline: July 23, 2025.

Thanks for joining us at #EHA2025. Explore our congress presentations to stay updated on the latest advancements in #SickleCellDisease. Click to know more: #HemaSphere

View our new publication on #migraine focused on the efficacy and safety of a CGRP receptor antagonist among patients with migraine in Japan. #Neurology #Neurotwitter. Learn more:

Migraine Data Update. Results from a just published #migraine acute treatment study. Full publication: #neurology.#healthcare.#neurotwitter

Pfizer is proud to share BASIS Phase 3 efficacy & safety results for a treatment for hemophilia A/B without inhibitors at 12 months: . Follow #PfizerMedical to stay up to date on our latest research in #hemophilia.

Pfizer is excited to share topline results from the BASIS Phase 3 study in #hemophilia A or B with inhibitors. Learn more at

Missed us at #ISTH2025? Catch up on the latest #hemophilia research from Pfizer. Posters and presentations are now available on the #PfizerMedical site:

Does your organization treat patients with #hemophilia? Apply to Pfizer’s competitive #grant supporting quality improvement initiatives for shared decision making in hemophilia patient care. Learn more at Deadline: July 23, 2025.

Visit the Pfizer medical website to view our latest #migraine and CGRP receptor antagonist research presented at #EAN2025. #healthcare